MedPath

Ramipril

Generic Name
Ramipril
Brand Names
Altace, Altace HCT
Drug Type
Small Molecule
Chemical Formula
C23H32N2O5
CAS Number
87333-19-5
Unique Ingredient Identifier
L35JN3I7SJ

Overview

Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

Background

Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

Indication

For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.

Associated Conditions

  • Cardiovascular Events
  • Diabetic Nephropathy
  • Heart Failure
  • Hearth Failure With Reduced Ejection Fraction (HFrEF)
  • Hypertension
  • Myocardial Infarction
  • Nondiabetic proteinuric chronic kidney disease
  • Stroke
  • High risk cardiovascular event

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2018/02/22
N/A
Recruiting
2018/01/30
Phase 1
Completed
2017/06/28
Phase 4
UNKNOWN
2017/04/04
Phase 4
Completed
2017/01/05
Phase 4
Completed
2016/10/05
Phase 3
Completed
2016/09/15
Phase 4
Completed
2016/07/22
Phase 4
Recruiting
2016/07/14
Phase 4
Completed
Sao Jose do Rio Preto Medical School
2016/06/07
Phase 2
UNKNOWN

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Carilion Materials Management
68151-0681
ORAL
1.25 mg in 1 1
6/6/2016
Exelan Pharmaceuticals, Inc.
76282-272
ORAL
2.5 mg in 1 1
8/27/2016
Physicians Total Care, Inc.
54868-5856
ORAL
2.5 mg in 1 1
1/31/2013
A-S Medication Solutions
50090-1120
ORAL
10 mg in 1 1
11/8/2022
Proficient Rx LP
63187-644
ORAL
2.5 mg in 1 1
12/1/2018
DIRECT RX
61919-833
ORAL
10 mg in 1 1
2/9/2016
Medsource Pharmaceuticals
45865-441
ORAL
10 mg in 1 1
12/27/2019
Aurobindo Pharma Limited
65862-475
ORAL
2.5 mg in 1 1
11/8/2022
A-S Medication Solutions
50090-4597
ORAL
5 mg in 1 1
3/1/2021
Zydus Pharmaceuticals USA Inc.
68382-147
ORAL
10 mg in 1 1
11/7/2023

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath